Brief: Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data From Vtp-300 In Chronic Hepatitis B Virus Infections
12/06/2024 22:31
Barinthus Biotherapeutics PLC 2ABy.F :
* BARINTHUS BIO ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION
FOLLOWING POSITIVE INTERIM DATA FROM VTP-300 IN CHRONIC
HEPATITIS B VIRUS INFECTIONS
* VACCITECH PLC - PIPELINE PRIORITIZATION IS EXPECTED TO
RESULT IN
A REDUCTION IN WORKFORCE OF APPROXIMATELY 25%
Source text for Eikon: ID:nGNX123lx4
Further company coverage: 2ABy.F
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing